Discounted Cash Flow
Vertex Pharmaceuticals Inc. / MA
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $1.7b | $-112.1m | $179.5m | -6.6% | $-0.46 |
| 2017 | $2.5b (46.2%) | $263.5m (335.1%) | $745.5m (315.2%) | 10.6% (260.8%) | $1.06 (330.4%) |
| 2018 | $3.0b (22.5%) | $2.1b (695.8%) | $1.2b (57.6%) | 68.8% (549.9%) | $8.24 (677.4%) |
| 2019 | $4.2b (36.6%) | $1.2b (-43.9%) | $1.5b (27.2%) | 28.3% (-58.9%) | $4.58 (-44.4%) |
| 2020 | $6.2b (49.1%) | $2.7b (130.4%) | $3.0b (100.4%) | 43.7% (54.6%) | $10.44 (127.9%) |
| 2021 | $7.6b (22.1%) | $2.3b (-13.6%) | $2.4b (-19.5%) | 30.9% (-29.2%) | $9.09 (-12.9%) |
| 2022 | $8.9b (17.9%) | $3.3b (41.8%) | $3.9b (63.0%) | 37.2% (20.3%) | $12.97 (42.7%) |
| 2023 | $9.9b (10.5%) | $3.6b (9.0%) | $3.3b (-15.0%) | 36.7% (-1.4%) | $14.05 (8.3%) |
| 2024 | $11.0b (11.7%) | $-535.6m (-114.8%) | $-790.3m (-123.7%) | -4.9% (-113.3%) | $-2.08 (-114.8%) |
| 2025 | $12.0b (8.9%) | $4.0b (838.1%) | $3.2b (504.1%) | 32.9% (777.7%) | $15.46 (843.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.